Patients studied
Patients . | Mayo patients . | ECOG patients . |
|---|---|---|
| Included in this study, no. | 109* | 199 |
| Studied for IgH translocation by clg-FISH† | 80 | 199 |
| Patients with normal IgH, no. (%) | 36 (45) | 78 (39) |
| Patients with translocated IgH, no. (%) | 44 (55) | 121 (61) |
| t(11;14)(q13;q32) karyotype‡ | 29 | NA |
| Patients with DNA ploidy studies done | ND | 199 |
Patients . | Mayo patients . | ECOG patients . |
|---|---|---|
| Included in this study, no. | 109* | 199 |
| Studied for IgH translocation by clg-FISH† | 80 | 199 |
| Patients with normal IgH, no. (%) | 36 (45) | 78 (39) |
| Patients with translocated IgH, no. (%) | 44 (55) | 121 (61) |
| t(11;14)(q13;q32) karyotype‡ | 29 | NA |
| Patients with DNA ploidy studies done | ND | 199 |
All patients have been previously studied for the t(11;14)(q13;q32), t(4;14)(p16.3;q32) and t(14;16)(q32;q23).
FISH indicates fluorescent in situ hybridization; NA, not applicable; ND, not done.
Includes both the 80 patients with available samples that were studied for IgH break-apart and the 29 patients with the t(11;14)(q13;q32).
Patients were selected for further study on the basis of the availability of samples for FISH investigation.
All together, 60% of patients had an IgH translocation if the 11% in whom it was detected by karyotype (29 of 254 patients) and 55% of the remaining 89% of patients are summed together.